Sanjiv Patel, MD
Family Medicine · Moorestown, NJNPI 1720113962
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,945 of the $14,367 with a category attached, or 69.2%. AbbVie accounts for 80.4% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2020 at $11,623 and has fallen 93.2% since, to $785 in 2025. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $67.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- AstraZeneca$491
- Lilly USA, LLC$294
- Novo Nordisk$261
- Pfizer$232
- Boehringer Ingelheim$188
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$9,94569%
- Travel & lodging$1,0367%
- Food & beverage$3,38624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $11,557 |
| AstraZeneca | 32 | $491 |
| Lilly USA, LLC | 17 | $294 |
| Novo Nordisk | 16 | $261 |
| Pfizer | 12 | $232 |
| Boehringer Ingelheim | 6 | $188 |
| GSK | 12 | $180 |
| Exact Sciences | 6 | $138 |
| Teva Pharmaceuticals USA, Inc. | 7 | $110 |
| Merck | 7 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Amgen | 4 | $59 |
| Astellas Pharma US Inc | 4 | $57 |
| Novartis | 4 | $52 |
| Adlon Therapeutics L.p. | 4 | $52 |
| Abbott | 2 | $48 |
| Johnson & Johnson | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Lundbeck LLC | 2 | $33 |
| UCB, Inc. | 2 | $30 |
| Almatica Pharma LLC | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $27 |
| Organon | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Neotract Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,367 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $94,310 |
| EliquisApixaban | 87 | $74,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,319 |
| TrulicityDulaglutide | 23 | $22,575 |
| JardianceEmpagliflozin | 23 | $22,329 |
| XareltoRivaroxaban | 25 | $19,742 |
| LinzessLinaclotide | 13 | $17,184 |
| MounjaroTirzepatide | 11 | $13,052 |
| FarxigaDapagliflozin Propanediol | 16 | $12,717 |
| JanuviaSitagliptin Phosphate | 14 | $10,360 |
| EntrestoSacubitril/Valsartan | 16 | $8,754 |
| Atorvastatin Calcium | 488 | $6,256 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 15 | $4,809 |
| Icosapent Ethyl | 16 | $4,803 |
| Levothyroxine Sodium | 367 | $4,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $261 | $94,31084 claims |
| PfizerEliquis | $232 | $74,38587 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $294 | $35,62734 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $180 | $27,38446 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $188 | $24,95534 claims |
| Johnson & JohnsonXarelto | $45 | $19,74225 claims |
| AbbVieLinzess, Synthroid | $11,557 | $18,79648 claims |
| AstraZenecaFarxiga | $491 | $12,71716 claims |
| MerckJanuvia | $96 | $10,36014 claims |
| NovartisEntresto | $52 | $8,75416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Moorestown
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.